CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...